CSPC has a very strong financial position. As of 2022, its total debt outstanding is only 1.8% of its total cash in hand. Its annual capital expenditure for 2022 was CNY 1.8 billion.

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

CSPC Innovation Pharmaceutical is trading at CN¥27.41, slightly below its estimated fair value of CN¥31.16, ... There are no important events for this country at this time.

CSPC Pharmaceutical Group, with a market cap of HK$50.61 billion, has been actively expanding its R&D efforts despite recent revenue challenges due to declining caffeine prices and health food sales.

Under the terms of the agreement, CSPC will receive $110 million as an upfront payment. The deal also includes potential milestone payments of up to $5.22 billion.

AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. | AstraZeneca ...

CSPC Pharma gets an upfront fee of up to $150 million, development payments of up to $135 million and further fees of up to $1.55 billion if it hits sales milestones, as well as royalties.